<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240514001027&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240514001027&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 14 May 2024 04:10:28 +0000</lastbuilddate>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):627-632. doi: 10.1161/CIRCULATIONAHA.124.068812. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739713</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068812>10.1161/CIRCULATIONAHA.124.068812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739713</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38739713</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068812</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18248</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739712/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):e935. doi: 10.1161/CIR.0000000000001215. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739712/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739712</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001215>10.1161/CIR.0000000000001215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739712</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18248</dc:title>
<dc:identifier>pmid:38739712</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001215</dc:identifier>
</item>
<item>
<title>Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1565-1567. doi: 10.1161/CIRCULATIONAHA.124.069124. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739700</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069124>10.1161/CIRCULATIONAHA.124.069124</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739700</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Lewis J Rubin</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?</dc:title>
<dc:identifier>pmid:38739700</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069124</dc:identifier>
</item>
<item>
<title>Correction to: An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739699/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):e1189-e1190. doi: 10.1161/CIR.0000000000001255. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739699/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739699</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001255>10.1161/CIR.0000000000001255</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739699</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial</dc:title>
<dc:identifier>pmid:38739699</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001255</dc:identifier>
</item>
<item>
<title>Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1543-1545. doi: 10.1161/CIRCULATIONAHA.123.067547. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739698</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067547>10.1161/CIRCULATIONAHA.123.067547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739698</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Stanley L Hazen</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases</dc:title>
<dc:identifier>pmid:38739698</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067547</dc:identifier>
</item>
<item>
<title>Closure of Coal-Burning Plant in Pittsburgh Linked to Big Reductions in Heart-Related Emergency Department Visits and Hospitalizations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1611-1613. doi: 10.1161/CIRCULATIONAHA.123.067602. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739697</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067602>10.1161/CIRCULATIONAHA.123.067602</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739697</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Bridget M Kuehn</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Closure of Coal-Burning Plant in Pittsburgh Linked to Big Reductions in Heart-Related Emergency Department Visits and Hospitalizations</dc:title>
<dc:identifier>pmid:38739697</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067602</dc:identifier>
</item>
<item>
<title>Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1546-1548. doi: 10.1161/CIRCULATIONAHA.123.067786. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739696</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067786>10.1161/CIRCULATIONAHA.123.067786</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739696</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Norman Stockbridge</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials</dc:title>
<dc:identifier>pmid:38739696</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067786</dc:identifier>
</item>
<item>
<title>Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>Defining mechanisms of cardiomyocyte proliferation should guide the understanding of endogenous cardiac regeneration and could lead to novel treatments for diseases such as myocardial infarction. In the neonatal heart, energy metabolic reprogramming (phenotypic alteration of glucose, fatty acid, and amino acid metabolism) parallels cell cycle arrest of cardiomyocytes. The metabolic reprogramming occurring shortly after birth is associated with alterations in blood oxygen levels, metabolic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1598-1610. doi: 10.1161/CIRCULATIONAHA.123.065880. Epub 2024 May 13.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Defining mechanisms of cardiomyocyte proliferation should guide the understanding of endogenous cardiac regeneration and could lead to novel treatments for diseases such as myocardial infarction. In the neonatal heart, energy metabolic reprogramming (phenotypic alteration of glucose, fatty acid, and amino acid metabolism) parallels cell cycle arrest of cardiomyocytes. The metabolic reprogramming occurring shortly after birth is associated with alterations in blood oxygen levels, metabolic substrate availability, hemodynamic stress, and hormone release. In the adult heart, myocardial infarction causes metabolic reprogramming but these changes cannot stimulate sufficient cardiomyocyte proliferation to replace those lost by the ischemic injury. Some putative pro-proliferative interventions can induce the metabolic reprogramming. Recent data show that altering the metabolic enzymes PKM2 [pyruvate kinase 2], LDHA [lactate dehydrogenase A], PDK4 [pyruvate dehydrogenase kinase 4], SDH [succinate dehydrogenase], CPT1b [carnitine palmitoyl transferase 1b], or HMGCS2 [3-hydroxy-3-methylglutaryl-CoA synthase 2] is sufficient to partially reverse metabolic reprogramming and promotes adult cardiomyocyte proliferation. How metabolic reprogramming regulates cardiomyocyte proliferation is not clearly defined. The possible mechanisms involve biosynthetic pathways from the glycolysis shunts and the epigenetic regulation induced by metabolic intermediates. Metabolic manipulation could represent a new approach to stimulate cardiac regeneration; however, the efficacy of these manipulations requires optimization, and novel molecular targets need to be defined. In this review, we summarize the features, triggers, and molecular regulatory networks responsible for metabolic reprogramming and discuss the current understanding of metabolic reprogramming as a critical determinant of cardiomyocyte proliferation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739695</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065880>10.1161/CIRCULATIONAHA.123.065880</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739695</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaokang Chen</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:creator>Ya Liu</dc:creator>
<dc:creator>Lingyan Liu</dc:creator>
<dc:creator>Steven R Houser</dc:creator>
<dc:creator>Wei Eric Wang</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?</dc:title>
<dc:identifier>pmid:38739695</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065880</dc:identifier>
</item>
<item>
<title>Augmented Cardiac Inotropy by Phosphodiesterase Inhibition Requires Phosphorylation of Rad and Increased Calcium Current</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739694/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1617-1620. doi: 10.1161/CIRCULATIONAHA.123.067298. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739694/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739694</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067298>10.1161/CIRCULATIONAHA.123.067298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739694</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander N Katchman</dc:creator>
<dc:creator>Sergey I Zakharov</dc:creator>
<dc:creator>Michael S Bohnen</dc:creator>
<dc:creator>Alejandro Sanchez Jimenez</dc:creator>
<dc:creator>Jared S Kushner</dc:creator>
<dc:creator>Lin Yang</dc:creator>
<dc:creator>Bi-Xing Chen</dc:creator>
<dc:creator>Amina Nasari</dc:creator>
<dc:creator>Guoxia Liu</dc:creator>
<dc:creator>David E Rabbani</dc:creator>
<dc:creator>Jiying Han</dc:creator>
<dc:creator>Cheng-Shiun Leu</dc:creator>
<dc:creator>Geoffrey S Pitt</dc:creator>
<dc:creator>Steven O Marx</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Augmented Cardiac Inotropy by Phosphodiesterase Inhibition Requires Phosphorylation of Rad and Increased Calcium Current</dc:title>
<dc:identifier>pmid:38739694</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067298</dc:identifier>
</item>
<item>
<title>Left Ventricular Hypertrophy With Preexcitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739693/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1614-1616. doi: 10.1161/CIRCULATIONAHA.124.069364. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739693/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739693</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069364>10.1161/CIRCULATIONAHA.124.069364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739693</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Maithree Mahesh</dc:creator>
<dc:creator>Mohsin Raj Mantoo</dc:creator>
<dc:creator>Nayani Makkar</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Left Ventricular Hypertrophy With Preexcitation</dc:title>
<dc:identifier>pmid:38739693</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069364</dc:identifier>
</item>
<item>
<title>Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739118/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide improved heart failure-related symptoms and physical limitations across diuretic use subgroups, with more pronounced benefits among patients receiving loop diuretics at baseline. Reductions in weight and improvements in exercise function with semaglutide versus placebo were consistent in all diuretic use categories. Semaglutide also led to a reduction in loop diuretic use and dose between baseline and 52 weeks.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 13:ehae322. doi: 10.1093/eurheartj/ehae322. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In the STEP-HFpEF trial program, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM trials (n=1145), which randomized participants with HFpEF and body mass index ≥30 kg/m2 to once weekly semaglutide 2.4 mg or placebo for 52 weeks, we examined whether efficacy and safety endpoints differed by baseline diuretic use, as well as the effect of semaglutide on loop diuretic use and dose changes over the 52-week treatment period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, across no diuretic (n=220), non-loop diuretic only (n=223), and loop diuretic (&lt;40 [n=219], 40 [n=309], and >;40 [n=174] mg/day furosemide-equivalents) groups, there was progressively higher prevalence of hypertension and atrial fibrillation; and severity of obesity and heart failure. Over 52 weeks of treatment, semaglutide had a consistent beneficial effect on change in body weight across diuretic use categories (adjusted mean difference vs. placebo ranged from -8.8% [95% CI -10.3, -6.3] to -6.9% [95% CI -9.1, -4.7] from no diuretics to the highest loop diuretic dose category; interaction P=0.39). Kansas City Cardiomyopathy Questionnaire clinical summary score improvement was greater in patients on loop diuretics compared to those not on loop diuretics (adjusted mean difference vs. placebo: +9.3 [6.5; 12.1] vs. +4.7 points [1.3, 8.2]; P=0.042). Semaglutide had consistent beneficial effects on all secondary efficacy endpoints (including 6-min walk distance) across diuretic subgroups (interaction P=0.24-0.92). Safety also favored semaglutide versus placebo across the diuretic subgroups. From baseline to 52 weeks, loop diuretic dose decreased by 17% in the semaglutide group vs. a 2.4% increase in the placebo group (P&lt;0.0001). Semaglutide (vs. placebo) was more likely to result in loop diuretic dose reduction (odds ratio [OR] 2.67 [95% CI 1.70, 4.18]) and less likely dose increase (OR 0.35 [95% CI 0.23, 0.53]; P&lt;0.001 for both) from baseline to 52 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide improved heart failure-related symptoms and physical limitations across diuretic use subgroups, with more pronounced benefits among patients receiving loop diuretics at baseline. Reductions in weight and improvements in exercise function with semaglutide versus placebo were consistent in all diuretic use categories. Semaglutide also led to a reduction in loop diuretic use and dose between baseline and 52 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS.GOV REGISTRATION: NCT04788511 and NCT04916470.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739118/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739118</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae322>10.1093/eurheartj/ehae322</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739118</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Melanie Davies</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Shachi Patel</dc:creator>
<dc:creator>Khaja M Chinnakondepalli</dc:creator>
<dc:creator>Mette N Einfeldt</dc:creator>
<dc:creator>Thomas J Jensen</dc:creator>
<dc:creator>Søren Rasmussen</dc:creator>
<dc:creator>Rabea Asleh</dc:creator>
<dc:creator>Tuvia Ben-Gal</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials</dc:title>
<dc:identifier>pmid:38739118</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae322</dc:identifier>
</item>
<item>
<title>Mineralocorticoid Receptor Antagonism in Heart Failure and Chronic Kidney Disease: Short-Term Pain for Long-Term Gain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739066/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 6:S0735-1097(24)06944-4. doi: 10.1016/j.jacc.2024.04.013. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739066</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.013>10.1016/j.jacc.2024.04.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739066</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Charles J Ferro</dc:creator>
<dc:creator>Jonathan N Townend</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mineralocorticoid Receptor Antagonism in Heart Failure and Chronic Kidney Disease: Short-Term Pain for Long-Term Gain</dc:title>
<dc:identifier>pmid:38739066</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.013</dc:identifier>
</item>
<item>
<title>Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739065/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The baseline 6MWT distance can refine risk stratification beyond traditional prognosticators. A worsening 6MWT distance can stratify disease progression and, when combined with established markers, identifies patients at the highest risk of mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7:S0735-1097(24)06893-1. doi: 10.1016/j.jacc.2024.04.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The 6-minute walk test (6MWT) represents a comprehensive functional assessment that is commonly used in patients with heart failure; however, data are lacking in patients with transthyretin cardiac amyloidosis (ATTR-CA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to assess the prognostic importance of the 6MWT in patients with ATTR-CA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A retrospective analysis of patients diagnosed with ATTR-CA at the National Amyloidosis Centre who underwent a baseline 6MWT between 2011 and 2023 identified 2,141 patients, of whom 1,118 had follow-up at 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median baseline 6MWT distance was 347 m (Q1-Q3: 250-428 m) and analysis by quartiles demonstrated an increased death rate with each distance reduction (deaths per 100 person-years: 6.3 vs 9.2 vs 13.6 vs 19.0; log-rank P &lt; 0.001). A 6MWT distance of &lt;350 m was associated with a 2.2-fold higher risk of mortality (HR: 2.15; 95% CI: 1.85-2.50; P &lt; 0.001), with a similar increased risk across National Amyloidosis Centre disease stages (P for interaction = 0.761) and genotypes (P for interaction = 0.172). An absolute (reduction of >;35 m) and relative worsening (reduction of >;5%) of 6MWT at 1 year was associated with an increased risk of mortality (HR: 1.80; 95% CI: 1.51-2.15; P &lt; 0.001 and HR: 1.89; 95% CI: 1.59-2.24; P &lt; 0.001, respectively), which was similar across the aforementioned subgroups. When combined with established measures of disease progression (N-terminal pro-B-type natriuretic peptide progression and outpatient diuretic intensification), each incremental increase in progression markers was associated with an increased death rate (deaths per 100 person-years: 7.6 vs 13.9 vs 22.4 vs 32.9; log-rank P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The baseline 6MWT distance can refine risk stratification beyond traditional prognosticators. A worsening 6MWT distance can stratify disease progression and, when combined with established markers, identifies patients at the highest risk of mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739065/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739065</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.011>10.1016/j.jacc.2024.04.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739065</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Carlo Fumagalli</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Muhammad U Rauf</dc:creator>
<dc:creator>Ana Martinez-Naharro</dc:creator>
<dc:creator>Lucia Venneri</dc:creator>
<dc:creator>William Moody</dc:creator>
<dc:creator>Richard P Steeds</dc:creator>
<dc:creator>Aviva Petrie</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Ashutosh Wechalekar</dc:creator>
<dc:creator>Helen Lachmann</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis</dc:title>
<dc:identifier>pmid:38739065</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.011</dc:identifier>
</item>
<item>
<title>Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Because patients experiencing a decrease in eGFR to &lt;30 mL/min/1.73 m² are at very high risk, the absolute risk reduction with an MRA in these patients is large and this decline in eGFR should not automatically lead to treatment discontinuation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 6:S0735-1097(24)06945-6. doi: 10.1016/j.jacc.2024.03.426. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Kidney dysfunction often leads to reluctance to start or continue life-saving heart failure (HF) therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to examine the efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with HF with reduced ejection fraction experiencing significant kidney dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We pooled individual patient data from the RALES (Randomized Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trials. The association between MRA treatment and outcomes was assessed according to whether the estimated glomerular filtration rate (eGFR) declined to &lt;30 mL/min/1.73 m<sup>2</sup> or not. The primary outcome was cardiovascular death or HF hospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4,355 patients included, 295 (6.8%) experienced a deterioration of eGFR after randomization to &lt;30 mL/min/1.73 m<sup>2</sup>. These patients had more impaired baseline cardiac and kidney function (eGFR 47.3 ± 13.4 mL/min/1.73 m<sup>2</sup> vs 70.5 ± 21.8 mL/min/1.73 m<sup>2</sup>) and had a higher risk of the primary outcome than patients without eGFR deterioration (HR: 2.49; 95% CI: 2.01-3.08; P &lt; 0.001). However, the risk reduction in the primary outcome with MRA therapy was similar in those who experienced a decrease in eGFR to &lt;30 mL/min/1.73 m<sup>2</sup> (HR: 0.65; 95% CI: 0.43-0.99) compared with those who did not (HR: 0.63; 95% CI: 0.56-0.71) (P<sub>interaction</sub> = 0.87). In patients with a decrease in eGFR to &lt;30 mL/min/1.73 m<sup>2</sup>, 21 fewer individuals (per 100 person-years) experienced the primary outcome with MRA treatment, vs placebo, compared with an excess of 3 more patients with severe hyperkalemia (>;6.0 mmol/L).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Because patients experiencing a decrease in eGFR to &lt;30 mL/min/1.73 m<sup>2</sup> are at very high risk, the absolute risk reduction with an MRA in these patients is large and this decline in eGFR should not automatically lead to treatment discontinuation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38739064</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.426>10.1016/j.jacc.2024.03.426</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739064</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Li Shen</dc:creator>
<dc:creator>Mingming Yang</dc:creator>
<dc:creator>Karl Swedberg</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function</dc:title>
<dc:identifier>pmid:38739064</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.426</dc:identifier>
</item>
<item>
<title>Focus on ischaemic heart disease: prevention with colchicine, role of the brain-heart axis, new therapeutic targets for ischaemia-reperfusion injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38738301/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 13;45(18):1577-1581. doi: 10.1093/eurheartj/ehae270.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38738301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38738301</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae270>10.1093/eurheartj/ehae270</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38738301</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on ischaemic heart disease: prevention with colchicine, role of the brain-heart axis, new therapeutic targets for ischaemia-reperfusion injury</dc:title>
<dc:identifier>pmid:38738301</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae270</dc:identifier>
</item>
<item>
<title>Spinal projecting neurons in rostral ventromedial medulla co-regulate motor and sympathetic tone</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>Many behaviors require the coordinated actions of somatic and autonomic functions. However, the underlying mechanisms remain elusive. By opto-stimulating different populations of descending spinal projecting neurons (SPNs) in anesthetized mice, we show that stimulation of excitatory SPNs in the rostral ventromedial medulla (rVMM) resulted in a simultaneous increase in somatomotor and sympathetic activities. Conversely, opto-stimulation of rVMM inhibitory SPNs decreased both activities....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 3:S0092-8674(24)00447-1. doi: 10.1016/j.cell.2024.04.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many behaviors require the coordinated actions of somatic and autonomic functions. However, the underlying mechanisms remain elusive. By opto-stimulating different populations of descending spinal projecting neurons (SPNs) in anesthetized mice, we show that stimulation of excitatory SPNs in the rostral ventromedial medulla (rVMM) resulted in a simultaneous increase in somatomotor and sympathetic activities. Conversely, opto-stimulation of rVMM inhibitory SPNs decreased both activities. Anatomically, these SPNs innervate both sympathetic preganglionic neurons and motor-related regions in the spinal cord. Fiber-photometry recording indicated that the activities of rVMM SPNs correlate with different levels of muscle and sympathetic tone during distinct arousal states. Inhibiting rVMM excitatory SPNs reduced basal muscle and sympathetic tone, impairing locomotion initiation and high-speed performance. In contrast, silencing the inhibitory population abolished muscle atonia and sympathetic hypoactivity during rapid eye movement (REM) sleep. Together, these results identify rVMM SPNs as descending spinal projecting pathways controlling the tone of both the somatomotor and sympathetic systems.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38733990</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.022>10.1016/j.cell.2024.04.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733990</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Zicong Zhang</dc:creator>
<dc:creator>Junfeng Su</dc:creator>
<dc:creator>Jing Tang</dc:creator>
<dc:creator>Leeyup Chung</dc:creator>
<dc:creator>Jessica C Page</dc:creator>
<dc:creator>Carla C Winter</dc:creator>
<dc:creator>Yuchu Liu</dc:creator>
<dc:creator>Evgenii Kegeles</dc:creator>
<dc:creator>Sara Conti</dc:creator>
<dc:creator>Yu Zhang</dc:creator>
<dc:creator>Jason Biundo</dc:creator>
<dc:creator>Joshua I Chalif</dc:creator>
<dc:creator>Charles Y Hua</dc:creator>
<dc:creator>Zhiyun Yang</dc:creator>
<dc:creator>Xue Yao</dc:creator>
<dc:creator>Yang Yang</dc:creator>
<dc:creator>Shuqiang Chen</dc:creator>
<dc:creator>Jan M Schwab</dc:creator>
<dc:creator>Kuan Hong Wang</dc:creator>
<dc:creator>Chinfei Chen</dc:creator>
<dc:creator>Michael J Prerau</dc:creator>
<dc:creator>Zhigang He</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Spinal projecting neurons in rostral ventromedial medulla co-regulate motor and sympathetic tone</dc:title>
<dc:identifier>pmid:38733990</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.022</dc:identifier>
</item>
<item>
<title>Perivascular neurons instruct 3D vascular lattice formation via neurovascular contact</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>The vasculature of the central nervous system is a 3D lattice composed of laminar vascular beds interconnected by penetrating vessels. The mechanisms controlling 3D lattice network formation remain largely unknown. Combining viral labeling, genetic marking, and single-cell profiling in the mouse retina, we discovered a perivascular neuronal subset, annotated as Fam19a4/Nts-positive retinal ganglion cells (Fam19a4/Nts-RGCs), directly contacting the vasculature with perisomatic endfeet....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 6:S0092-8674(24)00405-7. doi: 10.1016/j.cell.2024.04.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The vasculature of the central nervous system is a 3D lattice composed of laminar vascular beds interconnected by penetrating vessels. The mechanisms controlling 3D lattice network formation remain largely unknown. Combining viral labeling, genetic marking, and single-cell profiling in the mouse retina, we discovered a perivascular neuronal subset, annotated as Fam19a4/Nts-positive retinal ganglion cells (Fam19a4/Nts-RGCs), directly contacting the vasculature with perisomatic endfeet. Developmental ablation of Fam19a4/Nts-RGCs led to disoriented growth of penetrating vessels near the ganglion cell layer (GCL), leading to a disorganized 3D vascular lattice. We identified enriched PIEZO2 expression in Fam19a4/Nts-RGCs. Piezo2 loss from all retinal neurons or Fam19a4/Nts-RGCs abolished the direct neurovascular contacts and phenocopied the Fam19a4/Nts-RGC ablation deficits. The defective vascular structure led to reduced capillary perfusion and sensitized the retina to ischemic insults. Furthermore, we uncovered a Piezo2-dependent perivascular granule cell subset for cerebellar vascular patterning, indicating neuronal Piezo2-dependent 3D vascular patterning in the brain.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38733989</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.010>10.1016/j.cell.2024.04.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733989</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Kenichi Toma</dc:creator>
<dc:creator>Mengya Zhao</dc:creator>
<dc:creator>Shaobo Zhang</dc:creator>
<dc:creator>Fei Wang</dc:creator>
<dc:creator>Hannah K Graham</dc:creator>
<dc:creator>Jun Zou</dc:creator>
<dc:creator>Shweta Modgil</dc:creator>
<dc:creator>Wenhao H Shang</dc:creator>
<dc:creator>Nicole Y Tsai</dc:creator>
<dc:creator>Zhishun Cai</dc:creator>
<dc:creator>Liping Liu</dc:creator>
<dc:creator>Guiying Hong</dc:creator>
<dc:creator>Arnold R Kriegstein</dc:creator>
<dc:creator>Yang Hu</dc:creator>
<dc:creator>Jakob Körbelin</dc:creator>
<dc:creator>Ruobing Zhang</dc:creator>
<dc:creator>Yaping Joyce Liao</dc:creator>
<dc:creator>Tyson N Kim</dc:creator>
<dc:creator>Xin Ye</dc:creator>
<dc:creator>Xin Duan</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Perivascular neurons instruct 3D vascular lattice formation via neurovascular contact</dc:title>
<dc:identifier>pmid:38733989</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.010</dc:identifier>
</item>
<item>
<title>Redefining Iron Deficiency in Patients With Chronic Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.068883. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38733252</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068883>10.1161/CIRCULATIONAHA.124.068883</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733252</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Paul R Kalra</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Khawaja M Talha</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Redefining Iron Deficiency in Patients With Chronic Heart Failure</dc:title>
<dc:identifier>pmid:38733252</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068883</dc:identifier>
</item>
<item>
<title>Identification of three mechanistic pathways for iron-deficient heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically with anaemia) can drive the depletion of cardiomyocyte iron, impairing contractile performance and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 11:ehae284. doi: 10.1093/eurheartj/ehae284. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically with anaemia) can drive the depletion of cardiomyocyte iron, impairing contractile performance and explaining why a transferrin saturation &lt; ≈15%-16% predicts the ability of intravenous iron to reduce the risk of major heart failure events in long-term trials (Type 1 iron-deficient heart failure). However, heart failure may be accompanied by intracellular iron depletion within skeletal muscle and cardiomyocytes, which is disproportionate to the findings of systemic iron biomarkers. Inflammation- and deconditioning-mediated skeletal muscle dysfunction-a primary cause of dyspnoea and exercise intolerance in patients with heart failure-is accompanied by intracellular skeletal myocyte iron depletion, which can be exacerbated by even mild hypoferraemia, explaining why symptoms and functional capacity improve following intravenous iron, regardless of baseline haemoglobin or changes in haemoglobin (Type 2 iron-deficient heart failure). Additionally, patients with advanced heart failure show myocardial iron depletion due to both diminished entry into and enhanced egress of iron from the myocardium; the changes in iron proteins in the cardiomyocytes of these patients are opposite to those expected from systemic iron deficiency. Nevertheless, iron supplementation can prevent ventricular remodelling and cardiomyopathy produced by experimental injury in the absence of systemic iron deficiency (Type 3 iron-deficient heart failure). These observations, taken collectively, support the possibility of three different mechanistic pathways for the development of iron-deficient heart failure: one that is driven through systemic iron depletion and impaired erythropoiesis and two that are characterized by disproportionate depletion of intracellular iron in skeletal and cardiac muscle. These mechanisms are not mutually exclusive, and all pathways may be operative at the same time or may occur sequentially in the same patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38733250</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae284>10.1093/eurheartj/ehae284</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733250</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Paul R Kalra</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Identification of three mechanistic pathways for iron-deficient heart failure</dc:title>
<dc:identifier>pmid:38733250</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae284</dc:identifier>
</item>
<item>
<title>Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 11:ehae323. doi: 10.1093/eurheartj/ehae323. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The effect of PA-guided HF therapy was evaluated in the MONITOR-HF trial among predefined subgroups based on age, sex, atrial fibrillation, diabetes mellitus, left ventricular ejection fraction, HF aetiology, cardiac resynchronisation therapy, and implantable cardioverter defibrillator. Outcome measures were based upon significance in the main trial and included quality of life, clinical, and PA pressure endpoints, and were assessed for each subgroup. Differential effects in relation to the subgroups were assessed with interaction terms. Both unadjusted and multiple testing adjusted interaction terms were presented.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The effects of PA monitoring on quality of life, clinical events, and PA pressure were consistent in the predefined subgroups, without any clinically relevant heterogeneity within or across all endpoint categories (all adjusted interaction P-values were nonsignificant). In the unadjusted analysis of the primary endpoint quality-of-life change, weak trends towards a less pronounced effect in older patients (Pinteraction = 0.03; adjusted Pinteraction = 0.33) and diabetics (Pinteraction = 0.01; adjusted Pinteraction = 0.06) were observed. However, these interaction effects did not persist after adjusting for multiple testing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38733175</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae323>10.1093/eurheartj/ehae323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733175</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>P R D Clephas</dc:creator>
<dc:creator>V W Zwartkruis</dc:creator>
<dc:creator>J Malgie</dc:creator>
<dc:creator>M W F van Gent</dc:creator>
<dc:creator>H P Brunner-La Rocca</dc:creator>
<dc:creator>M K Szymanski</dc:creator>
<dc:creator>V P van Halm</dc:creator>
<dc:creator>M L Handoko</dc:creator>
<dc:creator>W Kok</dc:creator>
<dc:creator>F W Asselbergs</dc:creator>
<dc:creator>R van Kimmenade</dc:creator>
<dc:creator>O Manintveld</dc:creator>
<dc:creator>N M D A van Mieghem</dc:creator>
<dc:creator>S L M A Beeres</dc:creator>
<dc:creator>M C Post</dc:creator>
<dc:creator>C J W Borleffs</dc:creator>
<dc:creator>R Tukkie</dc:creator>
<dc:creator>A Mosterd</dc:creator>
<dc:creator>G C M Linssen</dc:creator>
<dc:creator>R F Spee</dc:creator>
<dc:creator>M E Emans</dc:creator>
<dc:creator>T D J Smilde</dc:creator>
<dc:creator>J van Ramshorst</dc:creator>
<dc:creator>C Kirchhof</dc:creator>
<dc:creator>F Feenema-Aardema</dc:creator>
<dc:creator>C A da Fonseca</dc:creator>
<dc:creator>M van den Heuve</dc:creator>
<dc:creator>R Hazeleger</dc:creator>
<dc:creator>M van Eck</dc:creator>
<dc:creator>L van Heerebeek</dc:creator>
<dc:creator>H Boersma</dc:creator>
<dc:creator>M Rienstra</dc:creator>
<dc:creator>R A de Boer</dc:creator>
<dc:creator>J J Brugts</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial</dc:title>
<dc:identifier>pmid:38733175</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae323</dc:identifier>
</item>
<item>
<title>Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733145/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240514001027&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.069382. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733145/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240514001027&v=2.18.0.post9+e462414">38733145</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069382>10.1161/CIRCULATIONAHA.124.069382</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733145</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Vlado Perkovic</dc:creator>
<dc:creator>Meg Jardine</dc:creator>
<dc:creator>Hiddo J L Heerspink</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials</dc:title>
<dc:identifier>pmid:38733145</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069382</dc:identifier>
</item>





























</channel>
</rss>